-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 9, Flamingo Therapeutics announced an agreement with Ionis Pharmaceuticals to jointly develop RNA targeted therapies to treat various forms of cancer
.
This cooperation is an extension of the cooperation with Ionis on the FLAME discovery engine (Flamingo LncRNA Antisense Mining Engine) following the A round of financing completed by Flamingo in 2020
According to the terms of the agreement, the two companies will use Flamingo's expertise in oncology and long-chain non-coding RNA (lncRNA), combined with Ionis' expertise in RNA-targeted drug discovery and development, to advance drug candidates that are difficult to deal with traditional methods.
Targeted target
.
Flamingo's pipeline will include three clinical phase projects from Ionis: STAT-3, androgen receptor (AR) and IRF4 inhibitors, and a preclinical project targeting MALAT1, which is an excellent lncRNA target
.
Flamingo will also advance its proprietary discovery engine FLAME, which can search for a large class of undeveloped lncRNA targets in the human genome
According to the agreement, Ionis is eligible to receive milestone payments and royalties for future product sales of STAT3, AR, IRF4 and MALAT1 projects
.
Flamingo reserves all rights to all lncRNA projects except for its FLAME platform and MALAT1
Note: The original text has been deleted
Reference materials:
[1] Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology.
